Serum gastrin-17 concentration for prediction of upper gastrointestinal tract bleeding risk among peptic ulcer patients

BACKGROUND Serum gastrin-17(G-17),pepsinogen I(PGI),and pepsinogen II(PGII)concentrations regulate gastric acid secretion,and hypersecretion of gastric acid increases the risks of peptic ulcer and upper gastrointestinal bleeding.These associations suggest that serum G-17,PGI,and(or)PGII may predict gastrointestinal bleeding risk among peptic ulcer patients.AIM To evaluate the efficacies of serum G-17,PGI,PGII,and PGI/PGII ratio(PGR)for predicting upper gastrointestinal bleeding among peptic ulcer patients.METHODS A total of 199 patients diagnosed with peptic ulcer confirmed by gastroscopy and positivity for Helicobacter pylori by the 14C-urea breath test were recruited,including 107 patients with simple peptic ulcer and 92 cases complicated by upper gastrointestinal bleeding.Serum PGI,PGII,G-17,and PGR were measured by immune methods and compared between bleeding and non-bleeding groups by univariate analysis.The specificity and sensitivity of PGs and G-17 for evaluating upper gastrointestinal bleeding risk were then assessed by constructing receiver operating characteristic(ROC)curves.RESULTS Serum G-17 was significantly higher among peptic ulcer patients with upper gastrointestinal bleeding compared to simple peptic ulcer patients(25.34±14.29 vs 8.84±8.03 pmol/L,t=9.822,P<0.01),whereas serum PGI,PGII,and PGR did not differ significantly between bleeding and non-bleeding groups(all P>0.05).The risk of bleeding was significantly higher among peptic ulcer patients with elevated serum G-17(>15 pmol/L)compared to patients with normal or low serum G-17(73.2%vs 27.4%,χ2=40.72,P<0.01).The area under the ROC curve for serum G-17 was 0.866±0.024,and a cut-off of 9.86 pmol/L yielded 90.2%sensitivity and 68.2%specificity for distinguishing peptic ulcer with and without upper gastrointestinal bleeding.CONCLUSION Serum G-17 is significantly upregulated in peptic ulcer patients and higher levels are predictive of upper gastrointestinal bleeding.Conversely,serum PGI,PGII,and PGR have no predictive value.Further prospective studies are warranted to examine if high G-17 can be used to assess risk of bleeding prior to onset.

Management of acute nonvariceal upper gastrointestinal bleeding:Current policies and future perspectives

Acute upper gastrointestinal bleeding(UGIB) is a gastroenterological emergency with a mortality of 6%-13%.The vast majority of these bleeds are due to peptic ulcers.Nonsteroidal anti-inflammatory drugs and Helicobacter pylori are the main risk factors for peptic ulcer disease.Endoscopy has become the mainstay for diagnosis and treatment of acute UGIB,and is recommended within 24 h of presentation.Proton pump inhibitor(PPI) administration before endoscopy can downstage the bleeding lesion and reduce the need for endoscopic therapy,but has no effect on rebleeding,mortality and need for surgery.Endoscopic therapy should be undertaken for ulcers with high-risk stigmata,to reduce the risk of rebleeding.This can be done with a variety of modalities.High-dose PPI administration after endoscopy can prevent rebleeding and reduce the need for further intervention and mortality,particularly in patients with high-risk stigmata.

Characteristics of nonvariceal upper gastrointestinal hemorrhage in patients with chronic kidney disease

AIM:To evaluate the clinical characteristics of nonvariceal upper gastrointestinal hemorrhage(NGIH)in patients with chronic kidney disease(CKD).METHODS:From 2003 to 2010,a total of 72 CKD patients(male n=52,72.2%;female n=20,27.8%)who had undergone endoscopic treatments for NGIH were retrospectively identified.Clinical findings,endoscopic features,prognosis,rebleeding risk factors,and mortality-related factors were evaluated.The characteristics of the patients and rebleeding-related data were recorded for the following variables:gender,age,alcohol use and smoking history,past hemorrhage history,endoscopic findings(the cause,location,and size of the hemorrhage and the hemorrhagic state),therapeutic options for endoscopy,endoscopist experience,clinical outcomes,and mortality.RESULTS:The average size of the hemorrhagic site was 13.7±10.2 mm,and the most common hemorrhagic site in the stomach was the antrum(n=21,43.8%).The most frequent method of hemostasis was combination therapy(n=32,44.4%).The incidence of rebleeding was 37.5%(n=27),and 16.7%(n=12)of patients expired due to hemorrhage.In a multivariate analysis of the risk factors for rebleeding,alcoholism(OR=11.19,P=0.02),the experience of endoscopists(OR=0.56,P=0.03),and combination endoscopic therapy(OR=0.06,P=0.01)compared with monotherapy were significantly related to rebleeding after endoscopic therapy.In a risk analysis of mortality after endoscopic therapy,only rebleeding was related to mortality(OR=7.1,P=0.02).CONCLUSION:Intensive combined endoscopic treatments by experienced endoscopists are necessary for the treatment of NGIH in patients with CKD,especially when a patient is an alcoholic.

One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable

AIM: To calculate the proportion of potentially preventable hospitalizations due to peptic ulcer disease (PUD), erosive gastritis (EG) or duodenitis (ED).

Endoscopic hemoclip treatment for bleeding peptic ulcer

AIM To evaluate the efficacy of endoscopichemoclip in the treatment of bleeding pepticulcer.METHODS Totally,40 patients with F1a andFib hemorrhagic activity of peptic ulcers wereenrolled in this uncontrolled prospective studyfor endoscopic hemoclip treatment.We used anewly developed rotatable clip-device for theapplication of hemoclip(MD850)to stopbleeding.Endoscopy was repeated if there wasany sign or suspicion of rebleeding,and re-clipping was performed if necessary andfeasible.RESULTS Initial hemostatic rate by clippingwas 95%,and rebleeding rate was only 8%.Ultimate hemostatic rates were 87%,96%,and93% in the Fla and Flb subgroups,and totalcases,respectively.In patients with shock onadmission,hemoclipping achieved ultimatehemostasis of 71% and 83% in F1a and F1bsubgroups,respectively.Hemostasis reached100% in patients without shock regardless ofhemorrhagic activity being F1a or F1b.Theaverage number of clips used per case was 3.0(range 2-5).Spurting bleeders required moreclips on average than did oozing bleeders(3.4versus 2.8).We observed no obviouscomplications,no tissue injury,or impairmentof ulcer healing related to hemoclipping.CONCLUSION Endoscopic hemoclip placementis an effective and safe method.With theimprovement of the clip and application device,the procedure has become easier and much moreefficient.Endoscopic hemoclipping deservesfurther study in the treatment of bleeding pepticulcers.

Scoring systems for peptic ulcer bleeding: which one to use?

AIM To compare the Glasgow-Blatchford score(GBS), Rockall score(RS) and Baylor bleeding score(BBS) in predicting clinical outcomes and need for interventions in patients with bleeding peptic ulcers. METHODS Between January 2008 and December 2013, 1012consecutive patients admitted with peptic ulcer bleeding(PUB) were prospectively followed. The pre-endoscopic RS, BBS and GBS, as well as the post-endoscopic diagnostic scores(RS and BBS) were calculated for all patients according to their urgent upper endoscopy findings. Area under the receiver-operating characteristics(AUROC) curves were calculated for the prediction of lethal outcome, rebleeding, needs for blood transfusion and/or surgical intervention, and the optimal cutoff values were evaluated.RESULTS PUB accounted for 41.9% of all upper gastrointestinal tract bleeding, 5.2% patients died and 5.4% patients underwent surgery. By comparing the AUROC curves of the aforementioned pre-endoscopic scores, the RS best predicted lethal outcome(AUROC 0.82 vs 0.67 vs0.63, respectively), but the GBS best predicted need for hospital-based intervention or 30-d mortality(AUROC0.84 vs 0.57 vs 0.64), rebleeding(AUROC 0.75 vs 0.61 vs 0.53), need for blood transfusion(AUROC 0.83 vs0.63 vs 0.58) and surgical intervention(0.82 vs 0.63 vs 0.52) The post-endoscopic RS was also better than the post-endoscopic BBS in predicting lethal outcome(AUROC 0.82 vs 0.69, respectively).CONCLUSION The RS is the best predictor of mortality and the GBS is the best predictor of rebleeding, need for blood transfusion and/or surgical intervention in patients with PUB. There is no one 'perfect score' and we suggest that these two tests be used concomitantly.

Endoscopic findings in patients with upper gastrointestinal bleeding clinically classified into three risk groups prior to endoscopy

AIM: To investigate in a prospective study whether a simplifi ed clinical score prior to endoscopy in upper gastrointestinal bleeding (UGIB) patients was able to predict endoscopic findings at urgent endoscopy. METHODS: All consecutive UGIB patients referred to a single endoscopic center during a 16 mo period were enrolled. Before endoscopy patients were strati- fied according to a simple clinical score (T-score), including T1 (high-risk), T2 (intermediate-risk) and T3 (low-risk). Endoscopy was performed in all cases within 2 h, and high-risk stigmata were considered for further analysis. RESULTS: Out of the 436 patients included into the study, 126 (29%) resulted to be T1, 135 (31%) T2, and 175 (40%) T3. Overall, stigmata of recent haem-orrhage (SRH) were detected in 118 cases (27%). SRH occurred more frequently in T1 patients than in T2/T3 cases (85% vs 3.2%; χ2 = 304.5309, P < 0.001). Older age (t=3.311; P < 0.01) and presence of comor-bidities (χ2 = 14.7458; P < 0.01) were more frequently detected in T1 than in T2/T3 patients. CONCLUSION: Our simplifi ed clinical score appeared to be associated with the detection of endoscopic findings which may deserve urgent endoscopy. A further,randomised study is needed to assess its accuracy in safely scheduling endoscopy in UGIB patients.

Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding

AIM:To compare the recurrent bleeding after endoscopic injection of different epinephrine volumes with hemoclips in patients with bleeding peptic ulcer.METHODS:Between January 2005 and December 2009,150 patients with gastric or duodenal bleeding ulcer with major stigmata of hemorrhage and nonbleeding visible vessel in an ulcer bed(Forrest Ⅱa) were included in the study.Patients were randomized to receive a small-volume epinephrine group(15 to 25 mL injection group;Group 1,n = 50),a large-volume epinephrine group(30 to 40 mL injection group;Group 2,n = 50) and a hemoclip group(Group 3,n = 50).The rate of recurrent bleeding,as the primary outcome,was compared between the groups of patients included in the study.Secondary outcomes compared between the groups were primary hemostasis rate,permanent hemostasis,need for emergency surgery,30 d mortality,bleeding-related deaths,length of hospital stay and transfusion requirements.RESULTS:Initial hemostasis was obtained in all patients.The rate of early recurrent bleeding was 30%(15/50) in the small-volume epinephrine group(Group 1) and 16%(8/50) in the large-volume epinephrine group(Group 2)(P = 0.09).The rate of recurrent bleeding was 4%(2/50) in the hemoclip group(Group 3);the difference was statistically significant with regard to patients treated with either small-volume or large-volume epinephrine solution(P = 0.0005 and P = 0.045,respectively).Duration of hospital stay was significantly shorter among patients treated with hemoclips than among patients treated with epinephrine whereas there were no differences in transfusion requirement or even 30 d mortality between the groups.CONCLUSION:Endoclip is superior to both small and large volume injection of epinephrine in the prevention of recurrent bleeding in patients with peptic ulcer.

Proton-pump inhibitors for prevention of upper gastrointestinal bleeding in patients undergoing dialysis

AIM:To investigate the preventive effects of low-dose proton-pump inhibitors(PPIs) for upper gastrointestinal bleeding(UGIB) in end-stage renal disease.METHODS:This was a retrospective cohort study that reviewed 544 patients with end-stage renal disease who started dialysis at our center between 2005 and 2013.We examined the incidence of UGIB in 175 patients treated with low-dose PPIs and 369 patients not treated with PPIs(control group).RESULTS:During the study period, 41 patients developed UGIB, a rate of 14.4/1000 person-years.The mean time between the start of dialysis and UGIB events was 26.3 ± 29.6 mo.Bleeding occurred in only two patients in the PPI group(2.5/1000 person-years) and in 39 patients in the control group(19.2/1000 person-years).Kaplan-Meier analysis of cumulative non-bleeding survival showed that the probability of UGIB was significantly lower in the PPI group than in the control group(log-rank test, P < 0.001).Univariate analysis showed that coronary artery disease, PPI use, anti-coagulation, and anti-platelet therapy were associated with UGIB.After adjustments for the potential factors influencing risk of UGIB, PPI use was shown to be significantly beneficial in reducing UGIB compared to the control group(HR = 13.7, 95%CI:1.8-101.6; P = 0.011).CONCLUSION:The use of low-dose PPIs in patients with end-stage renal disease is associated with a low frequency of UGIB.

Application of Nursing Risk Management in Nursing of Severe Peptic Ulcer Bleeding

Objective: To assess and compare the clinical application value of nursing risk management in the diagnosis and treatment of severe peptic ulcer bleeding. Methods: A total of 70 patients with severe peptic ulcer bleeding were selected as the research objects, randomly divided into observation group and control group, 35 cases for each. The nursing risk management and conventional nursing management were implemented for the two groups, respectively. The success rate of hemostasis, average length of stay, cure rate, complication rate, dyspnea rate, nursing dispute rate, SAS score, and SDS score were compared between the two groups. Patients’ satisfaction with nursing quality was also compared. Results: After the implementation of two different nursing management methods, all the above-mentioned metrics were better in the observation group than in the control group, and the differences were statistically significant (P < 0.01 or P < 0.05). Conclusion: The application of nursing risk management in the nursing intervention process of patients with severe peptic ulcer bleeding can effectively reduce the probability of nursing risk events, increase the cure rate, shorten the patient’s hospital stay, but also improve the patients’ psychological state and increase the patient’s satisfaction with nursing quality, which is worth clinical promotion.

Impact of epinephrine volume on further bleeding due to high-risk peptic ulcer disease in the combination therapy era

BACKGROUND In monotherapy studies for bleeding peptic ulcers,large volumes of epinephrine were associated with a reduction in rebleeding.However,the impact of epinephrine volume in patients treated with combination endoscopic therapy remains unclear.AIM To assess whether epinephrine volume was associated with bleeding outcomes in individuals who also received endoscopic thermal therapy and/or clipping.METHODS Data from 132 patients with Forrest class Ia,Ib,and IIa peptic ulcers were reviewed.The primary outcome was further bleeding at 7 d;secondary outcomes included further bleeding at 30 d,need for additional therapeutic interventions,post-endoscopy blood transfusions,and 30-day mortality.Logistic and linear regression and Cox proportional hazards analyses were performed.RESULTS There was no association between epinephrine volume and all primary and secondary outcomes in multivariable analyses.Increased odds for further bleeding at 7 d occurred in patients with elevated creatinine values(aOR 1.96,95%CI 1.30-3.20;P<0.01)or hypotension requiring vasopressors(aOR 6.34,95%CI 1.87-25.52;P<0.01).Both factors were also associated with all secondary outcomes.CONCLUSION Epinephrine maintains an important role in the management of bleeding ulcers,but large volumes up to a range of 10-20 mL are not associated with improved bleeding outcomes among individuals receiving combination endoscopic therapy.Further bleeding is primarily associated with patient factors that likely cannot be overcome by increased volumes of epinephrine.However,in carefully-selected cases where ulcer location or size pose therapeutic challenges or when additional modalities are unavailable,it is conceivable that increased volumes of epinephrine may still be beneficial.

基于信息-动机-行为技巧模型的知信行健康宣教及护理在消化性溃疡合并上消化道出血患者中的应用效果

目的研究基于信息-动机-行为技巧模型(IMB)的知信行健康宣教及护理在消化性溃疡合并上消化道出血患者中的应用效果。方法选择2021年3月至2022年10月安徽省安庆市立医院接受治疗的患者82例,根据随机数字表法将其分为对照组与观察组,各41例。对照组采用常规知信行宣教及护理进行干预,观察组在对照组的基础上给予基于IMB模型的知信行宣教及护理。比较两组干预前与出院1个月后药物依从性、疾病不确定感、自我效能。结果出院后1个月,两组依从性得分均高于干预前,且研究组高于对照组,差异有统计学意义(P<0.05)。出院后1个月,两组疾病不确定感各项得分均低于干预前,且观察组低于对照组,差异有统计学意义(P<0.05)。出院后1个月,两组自我效能得分均高于干预前,且观察组高于对照组,差异有统计学意义(P<0.05)。结论基于IMB模型的知信行健康宣教及护理,能够有效提高消化性溃疡合并上消化道出血患者的治疗效果,值得推广运用。

聚普瑞锌联合奥美拉唑治疗消化性溃疡导致的上消化道出血的临床价值研究

目的 分析聚普瑞锌颗粒联合奥美拉唑对消化性溃疡导致的上消化道出血患者治疗效果和不良反应的影响。方法 选取2017年1月—2023年11月阜宁县人民医院消化内科收治的60例消化性溃疡导致上消化道出血患者为研究对象,采用信封法分为两组,每组30例。对照组单纯采用奥美拉唑治疗,观察组在对照组基础上联合使用聚普瑞锌颗粒治疗。对比两组临床疗效、不良反应、症状积分。结果 观察组治疗总有效率(96.67%)高于对照组(73.33%),差异有统计学意义(χ^(2)=4.706,P<0.05)。观察组不良反应发生率(6.67%)低于对照组(26.67%),差异有统计学意义(χ^(2)=4.320,P<0.05)。观察组腹胀、腹痛、恶心呕吐症状积分均低于对照组,差异有统计学意义(P均<0.05)。结论 聚普瑞锌+奥美拉唑联合用于消化性溃疡导致的上消化道出血患者治疗中,具有理想治疗作用,可以改善患者症状和预后状态,减少不良反应的发生。

紫地合剂联合质子泵抑制剂治疗消化性溃疡出血的临床疗效观察

【目的】观察具有收敛止血、清热凉血功效的紫地合剂联合质子泵抑制剂(proton pump inhibitions,PPIs)治疗消化性溃疡出血(peptic ulcer bleeding,PUB)的临床效果。【方法】回顾性收集2019年12月至2023年5月在广州中医药大学第一附属医院急诊病区住院的281例PUB患者,根据治疗方案的不同将其分为对照组143例和观察组138例。对照组患者在一般治疗基础上给予PPIs治疗,观察组在对照组的基础上给予紫地合剂口服治疗,疗程为3 d。观察2组患者治疗前后格拉斯哥-布拉奇福德出血评分(GBS)、血红蛋白量(HGB)、血小板总数(PLT)、血尿素氮(BUN)、血肌酐(Cr)、谷草转氨酶(AST)、谷丙转氨酶(ALT)水平的变化情况,并比较2组患者的平均住院时间和临床疗效。【结果】(1)治疗3 d后,观察组的总有效率为97.10%(134/138),对照组为91.61%(131/143),组间比较(χ^(2)检验),观察组的疗效优于对照组,差异有统计学意义(P<0.05)。(2)治疗后,2组患者的GBS评分均较治疗前降低(P<0.05),且观察组对GBS评分的降低作用优于对照组,差异有统计学意义(P<0.05)。(3)观察组的平均住院时间为(5.81±1.02)d,较对照组的(6.13±1.12)d有所缩短,差异有统计学意义(P<0.05)。(4)治疗后,2组患者外周血HGB、PLT水平较治疗前升高(P<0.05),BUN水平较治疗前降低(P<0.05),且观察组对外周血HGB、PLT水平的升高作用及对BUN水平的降低作用均明显优于对照组,差异均有统计学意义(P<0.05)。(5)治疗过程中,2组患者的外周血AST、ALT、Cr水平均未见升高,差异均无统计学意义(P>0.05)。【结论】紫地合剂联合PPIs治疗PUB效果显著,有助于改善相关血常规和生化指标,缩短住院时间,其疗效优于单纯使用PPIs治疗。

消化性溃疡患者并发上消化道出血的危险因素分析

目的分析探讨消化性溃疡(PU)患者并发上消化道出血(UGH)的危险因素。方法选取2021年4月至2022年4月郑州市第九人民医院收治的90例PU患者作为研究对象,收集患者性别、年龄、溃疡长径、溃疡病程、溃疡部位、职业、有无吸烟史、有无饮酒史、是否合并幽门螺杆菌感染、入院时血清单核细胞趋化蛋白-1(MCP-1)水平、入院时CD4+水平、入院时CD8+水平、有无高血压病史、有无糖尿病病史、是否长时间应用非甾体抗炎药、是否合并UGH等资料,并根据患者是否合并UGH将其分为并发UGH组和未并发UGH组,多因素Logistic回归分析PU患者并发UGH的危险因素。结果90例PU患者中22例(24.44%)患者合并UGH,设为并发UGH组;68例(75.56%)患者未合并UGH,设为未并发UGH组。单因素分析结果显示,并发UGH组有饮酒史、长时间应用非甾体抗炎药患者比例明显高于未并发UGH组(χ^(2)=17.113、10.399,P<0.001、P=0.001),血清MCP-1水平、CD4+水平明显高于未并发UGH组(t=18.595、4.757,P均<0.001);多因素Logistic回归分析结果显示,有饮酒史、长时间应用非甾体抗炎药、血清MCP-1高水平、CD4+高水平是PU患者并发UGH的独立危险因素(95%CI为3.386~30.422、1.805~14.281、1.047~1.131、1.098~1.349,P<0.001、P=0.002、P<0.001、P<0.001)。结论PU患者并发UGH与饮酒史、非甾体抗炎药应用史以及MCP-1与CD4+水平密切相关,临床应予以重点关注,及时根据患者具体情况采取针对性干预措施,以预防UGH的发生。

清胃愈疡汤辅助奥美拉唑治疗消化道溃疡并发上消化道出血的有效性及安全性分析

目的探讨清胃愈疡汤辅助奥美拉唑治疗消化道溃疡(PU)并发上消化道出血的临床效果.方法选取2022年1月—2023年6月同济大学附属东方医院胶州医院收治的82例PU并发上消化道出血患者为研究对象,按随机数字表法将其分为对照组及观察组,每组41例.对照组采用奥美拉唑治疗,观察组在此基础上采用清胃愈疡汤治疗,均持续治疗8周.比较两组患者的临床疗效、疾病症状改善时间、血红蛋白、胃液pH值、炎症水平、临床症状积分及安全性.结果观察组的治疗总有效率为95.12%,高于对照组的80.49%,差异有统计学意义(P﹤0.05).观察组的止血、大便转黄、潜血转阴时间均短于对照组,组间差异有统计学意义(P﹤0.05).治疗后,观察组的血红蛋白水平、胃液pH值均高于对照组,组间差异有统计学意义(P﹤0.05);观察组的上腹部疼痛、胃部灼热、烧心反酸、恶心呕吐积分均低于对照组,组间差异有统计学意义(P﹤0.05).两组的安全性比较,差异无统计学意义(P﹥0.05).结论清胃愈疡汤辅助奥美拉唑可提高PU并发上消化道出血的治疗效果,加快疾病症状消失,安全可靠.

奥曲肽联合胃镜治疗消化性溃疡伴出血患者的临床效果

目的:分析奥曲肽联合胃镜治疗消化性溃疡伴出血患者的临床效果。方法:选择2021年1月—2023年1月曲靖市第一人民医院收治的200例消化性溃疡伴出血患者作为研究对象,根据治疗方法的不同分为对照组和观察组,各100例。对照组采用胃镜治疗,观察组在对照组的基础上加用奥曲肽治疗。比较两组的症状缓解时间、住院时间、疼痛程度、炎症因子指标、生活质量。结果:治疗后,观察组腹痛缓解时间、呕血停止时间、住院时间均短于对照组,差异有统计学意义(P<0.05);治疗后24 h、48 h,观察组视觉模拟评分法(VAS)评分均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组白细胞介素-2(IL-2)高于对照组,白细胞介素-6(IL-6)低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组健康调查简表(SF-36)各维度评分均高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:奥曲肽联合胃镜治疗消化性溃疡伴出血患者可较快缓解患者的呕血和疼痛症状,调节炎症因子指标,提升患者生活质量,促进患者早日康复出院。

白蛋白/铁蛋白比值与消化性溃疡患者并发上消化道出血的关系

目的探讨白蛋白/铁蛋白比值与消化性溃疡患者并发上消化道出血(UGIB)的关系。方法选取2019年10月至2022年3月无为市人民医院收治的130例消化性溃疡并发UGIB患者作为研究对象,根据出血程度分为轻中度出血组(n=98)与重度出血组(n=32)。收集所有患者的临床及生化指标资料。采用Pearson相关分析探讨白蛋白/铁蛋白比值与消化性溃疡患者UGIB严重程度的关系,采用受试者工作特性(ROC)曲线评价白蛋白/铁蛋白比值对消化性溃疡患者UGIB严重程度的评估价值,采用二分类Logistic逐步回归分析探讨消化性溃疡患者UGIB严重程度的影响因素。结果重度出血组患者的铁蛋白水平高于轻中度出血组,白蛋白、白蛋白/铁蛋白比值低于轻中度出血组,差异有统计学意义(P<0.05)。白蛋白/铁蛋白比值与消化性溃疡患者UGIB严重程度呈负相关(r=-0.629,P<0.001)。白蛋白、铁蛋白及白蛋白/铁蛋白比值评估消化性溃疡患者UGIB严重程度的AUC(95%CI)分别为0.819(0.769~0.867)、0.724(0.674~0.774),0.938(0.893~0.984)。两组性别、体质量指数、婚姻状况、文化程度、吸烟史、饮酒史、溃疡位置比较差异无统计学意义(P>0.05);重度出血组年龄≥60岁、月收入<2000元、溃疡直径≥20 mm、溃疡分期为活动期比例高于轻中度出血组,差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,溃疡直径≥20 mm(OR=2.843,95%CI:1.396~5.792),溃疡分期为活动期(OR=2.368,95%CI:1.302~4.305),白蛋白/铁蛋白比值<2.66(OR=4.559,95%CI:2.387~8.704)是消化性溃疡患者UGIB严重程度的影响因素(P<0.05)。结论低白蛋白/铁蛋白比值与消化性溃疡患者并发UGIB密切相关,可作为评估消化性溃疡患者UGIB严重程度的潜在生物学指标。

奥曲肽与泮托拉唑治疗消化性溃疡并发上消化道出血的疗效

目的探讨奥曲肽与泮托拉唑联合治疗消化性溃疡并发上消化道出血的效果。方法选取2018年5月—2020年12月在宁德师范学院附属宁德市医院接受治疗的70例消化性溃疡并发上消化道出血患者,基于随机数字表法分为对照组(n=35,给予“泮托拉唑”治疗)与观察组(n=35,给予“奥曲肽+泮托拉唑”治疗)。比较2组患者治疗效果及相关炎症因子水平情况。结果观察组与对照组治疗有效率[97.14%vs.82.85%]比较,差异有统计学意义(P<0.05)。观察组患者的黑便次数(0.60±0.19)次、止血时间(0.43±0.13)d、腹痛缓解时间(0.45±0.15)d,均明显低于对照组的(1.34±0.53)次、(1.06±0.42)d和(1.15±0.54)d(P<0.05)。观察组患者治疗后的血常规指标均明显优于对照组(P<0.05)。在炎症水平方面,观察组患者治疗后的炎症因子水平明显低于对照组,差异有统计学意义(P<0.05)。2组患者均未出现相关不良反应。结论对于消化并发上消化道出血,给予单一用药(泮托拉唑)的疗效不甚理想,但基于联合用药(“奥曲肽”与“泮托拉唑”)的综合效果更理想,可以有效控制出血、改善相关症状,并且血常规、炎症因子水平等改善效果更显著,用药安全。

血清MCP-1及PGE_(2)水平对消化性溃疡并发上消化道出血风险的预测价值

目的探讨消化性溃疡(PU)并发上消化道出血(UGIB)的危险因素,并分析血清单核细胞趋化因子1(MCP-1)及前列腺素E_(2)(PGE_(2))水平变化对PU并发UGIB风险的预测价值。方法回顾性选取2020年8月—2022年7月诊治的128例PU患者的临床资料,根据PU患者治疗结束3个月后是否发生UGIB分为UGIB组和非UGIB组,收集两组患者的基线资料及血清MCP-1、PGE_(2)水平变化;采用Logistic回归模型分析PU并发UGIB的危险因素;采用受试者工作特征(ROC)曲线模型分析MCP-1、PGE_(2)水平变化对PU患者发生UGIB的预测效能。结果共42例患者并发UGIB,纳入UGIB组;86例患者未发生UGIB,纳入非UGIB组。两组的吸烟史占比、溃疡位置、溃疡直径、MCP-1水平、PGE_(2)水平差异有统计学意义(P<0.05);多因素Logistic回归模型显示,溃疡位置、溃疡直径、MCP-1水平、PGE_(2)水平是影响PU患者并发UGIB的危险因素(P<0.05);ROC曲线分析显示,MCP-1、PGE_(2)水平及两项联合预测PU患者并发UGIB的曲线下面积(AUC)分别为0.798、0.784、0.934(P<0.05)。结论血清MCP-1、PGE_(2)对PU并发UGIB患者具有一定预测价值,尤其两项指标联合检测预测效能更高。